Search Within

Paul Chapman

Formats
  1. Journal Article (206)
  2. Meeting Abstract (109)
  3. Book Section (8)
  4. Conference Paper (1)
  5. Editorial (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (327)
  2. Department of Medicine (327)
  3. Melanoma and Immunotherapeutics Service (327)
  4. Solid Tumor Oncology Division (327)
  5. GSK Faculty (133)
  6. Melanoma Disease Management Team (93)

More Groups

People
  1. Jedd Wolchok (107)
  2. Katherine Panageas (77)
  3. Alan Houghton (60)
  4. Michael Postow (55)
  5. Margaret Callahan (50)
  6. Alexander Shoushtari (46)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (2)
  5. 2021 (9)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Clinical Cancer Research (29)
  3. Cancer Research (15)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (13)
  5. New England Journal of Medicine (11)
  6. Melanoma Research (10)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. American Association for Cancer Research (60)
  3. Elsevier Inc. (22)
  4. Lippincott Williams & Wilkins (19)
  5. Wiley Blackwell (19)
  6. Oxford University Press (13)

More Publishers

Results (327)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ipilimumab for patients with advanced mucosal melanoma
    Journal Article

    Postow, M. A.; Luke, J. J.; Bluth, M. J.; Ramaiya, N.; Panageas, K. S.; Lawrence, D. P.; Ibrahim, N.; Flaherty, K. T.; Sullivan, R. J.; Ott, P. A.; more...
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Journal Article

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)
    Meeting Abstract

    Kirkwood, J. M.; Long, G. V.; Trefzer, U.; Davies, M. A.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Kefford, R.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy
    Meeting Abstract

    Harding, J. J.; Lacouture, M. E.; Pulitzer, M.; Callahan, M.; Postow, M. A.; Carvajal, R. D.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma
    Meeting Abstract

    Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; Testori, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma
    Meeting Abstract

    Carvajal, R. D.; Ambrosini, G.; Wolchok, J. D.; Chapman, P. B.; Dickson, M. A.; D'Angelo, S. P.; Bluth, M. J.; Paucar, D.; Fusco, A.; Bohr, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Targeted inhibition of B-Raf
    Book Section

    Chapman, P. B.; Flaherty, K.
    In Gajewski, T. F.; Hodi, F. S. (Eds.) Targeted Therapeutics in Melanoma (2012)

    Fulltext@MSK | Save
  • Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience
    Meeting Abstract

    Khan, S. A.; Callahan, M.; Postow, M. A.; Chapman, P. B.; Schwartz, G. K.; Dickson, M. A.; D'Angelo, S. P.; Luke, J. J.; Bluth, M. J.; Roman, R. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors
    Meeting Abstract

    Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF(V600E)-mutated melanoma
    Meeting Abstract

    Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C. U.; Mirakhur, B.; Guckert, M. E.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save